Amendment to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1-21. (Cancelled).

22. (New) A sustained release pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier therefor, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione of at least 50 ng/mL over a period of 12 hours.

23. (New) A sustained release pharmaceutical composition according to claim 22, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione within the range of 50 to 200 ng/mL over a period of 12 hours.

24. (New) A sustained release pharmaceutical composition according to claim 22, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 120 ng/mL over a period of 12 hours.

25. (New) A sustained release pharmaceutical composition according to claim 22, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 100 ng/mL over a period of 12 hours.

26. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human

or non-human mammal in need thereof the pharmaceutical composition according to claim 22.

27. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 23.

28. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 24.

29. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 25.

30. (New) A sustained release pharmaceutical composition comprising 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable carrier therefor, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione of at least 50 ng/mL over a period of 16 hours.

31. (New) A sustained release pharmaceutical composition according to claim 30, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione within the range of 50 to 200 ng/mL over a period of 16 hours.

32. (New) A sustained release pharmaceutical composition according to claim 30, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-

methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 120 ng/mL over a period of 16 hours.

33. (New) A sustained release pharmaceutical composition according to claim 30, which composition is adapted to provide a plasma concentration of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in the range of 50 to 100 ng/mL over a period of 16 hours.

34. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 30.

35. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 31.

36. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 32.

37. (New) A method for the treatment of Type 2 diabetes mellitus and conditions associated with diabetes mellitus, which method comprises the administration to a human or non-human mammal in need thereof the pharmaceutical composition according to claim 33.